CuraTeQ Biologics
Biosimilar developer, India. 4 development products across 4 molecules: bevacizumab, filgrastim, pegfilgrastim, trastuzumab.
About CuraTeQ Biologics
CuraTeQ is the biologics arm of Aurobindo. It received its first European approval, for filgrastim, in February 2025, and followed within months with pegfilgrastim and trastuzumab, with a second pegfilgrastim name given a positive opinion in 2026. In India it holds permissions for trastuzumab and bevacizumab. It is the newest Indian company to reach Europe.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Bevacizumab | CuraTeQ bevacizumab | · | · | · | · | · | May 2026 | · | 1/7 |
| Filgrastim | Zefylti | · | Feb 2025 | MHRA | · | · | · | · | 2/7 |
| Pegfilgrastim | Dyrupeg / Cavoley | · | Mar 2025 | MHRA | · | · | · | · | 2/7 |
| Trastuzumab | Dazublys / CuraTeQ trastuzumab | · | Jun 2025 | MHRA | · | · | Mar 2024 | · | 3/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with CuraTeQ Biologics, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOMar 2024CuraTeQ Biologics Private (INN only), trastuzumab
- EMAFeb 2025Zefylti, filgrastim
- EMAMar 2025Dyrupeg, pegfilgrastim
- EMAJun 2025Dazublys, trastuzumab
- CDSCOMay 2026CuraTeQ Biologics Private (INN only), bevacizumab
Compare CuraTeQ Biologics with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant